| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698423 | Clinical Oncology | 2013 | 7 Pages |
Abstract
The use of MLC cardiac shielding reduces doses to cardiac tissues at the expense of target tissue coverage. Formal target volume delineation in combination with an assessment of the likelihood of local relapse is recommended in order to aid decisions regarding field and MLC placement.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
F.R. Bartlett, J.R. Yarnold, E.M. Donovan, P.M. Evans, I. Locke, A.M. Kirby,